release channel (CRC), causing the channel to open. To further examine the effects of AgNO 3 on the CRC and the Ca 2ϩ -ATPase, Ca 2ϩ release was measured in muscle homogenates prepared from rat hindlimb muscle using indo 1. Cyclopiazonic acid (CPA) and ruthenium red (RR) were used to inhibit the Ca 2ϩ -ATPase and block the CRC, respectively, before inducing Ca 2ϩ release with both AgNO3 and 4-chlorom-cresol (4-CMC), a releasing agent specific for the CRC. With AgNO3 and CPA, the early rapid rate of release (phase 1) was increased (P Ͻ 0.05) by 42% (314 Ϯ 5 vs. 446 Ϯ 39 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ), whereas the slower, more prolonged rate of release (phase 2) was decreased (P Ͻ 0.05) by 72% (267 Ϯ 39 vs. 74 Ϯ 7.7 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ). RR, in combination with AgNO3, had no effect on phase 1 (P Ͼ 0.05) (314 Ϯ 51 vs. 334 Ϯ 43 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ) and decreased phase 2 (P Ͻ 0.05) by 65% (245 Ϯ 34 vs. 105 Ϯ 8.2 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ). With 4-CMC, CPA had no effect (P Ͼ 0.05) on either phase 1 or 2. With addition of RR, phase 1 was reduced (P Ͻ 0.05) by 59% (2,468 Ϯ 279 vs.
To further examine the effects of AgNO 3 on the CRC and the Ca 2ϩ -ATPase, Ca 2ϩ release was measured in muscle homogenates prepared from rat hindlimb muscle using indo 1. Cyclopiazonic acid (CPA) and ruthenium red (RR) were used to inhibit the Ca 2ϩ -ATPase and block the CRC, respectively, before inducing Ca 2ϩ release with both AgNO3 and 4-chlorom-cresol (4-CMC), a releasing agent specific for the CRC. With AgNO3 and CPA, the early rapid rate of release (phase 1) was increased (P Ͻ 0.05) by 42% (314 Ϯ 5 vs. 446 Ϯ 39 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ), whereas the slower, more prolonged rate of release (phase 2) was decreased (P Ͻ 0.05) by 72% (267 Ϯ 39 vs. 74 Ϯ 7.7 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ). RR, in combination with AgNO3, had no effect on phase 1 (P Ͼ 0.05) (314 Ϯ 51 vs. 334 Ϯ 43 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ) and decreased phase 2 (P Ͻ 0.05) by 65% (245 Ϯ 34 vs. 105 Ϯ 8.2 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ). With 4-CMC, CPA had no effect (P Ͼ 0.05) on either phase 1 or 2. With addition of RR, phase 1 was reduced (P Ͻ 0.05) by 59% (2,468 Ϯ 279 vs. 1,004 Ϯ 87 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ), and RR completely blocked phase 2. Both AgNO3 and 4-CMC fully inhibited Ca 2ϩ -ATPase activity measured in homogenates. These findings indicate that AgNO3, but not 4-CMC, induces Ca 2ϩ release by acting on both the CRC and the Ca 2ϩ -ATPase.
calcium ion cycling; calcium ion release; calcium ion uptake; silver nitrate THE CONTRACTION-RELAXATION cycle of skeletal muscle is regulated by the release and accumulation of Ca 2ϩ by the sarcoplasmic reticulum (SR) (24) . T-tubule depolarization causes the rapid release of Ca 2ϩ from the SR store, via the Ca 2ϩ release channels (CRC), for the initiation of contraction. Subsequently, cytosolic Ca 2ϩ is rapidly decreased to allow muscle relaxation. The latter involves reuptake of the released Ca 2ϩ via the SR Ca 2ϩ -ATPase, which is an energy-dependent process (23) .
Loss of SR function, such as occurs during and after repeated intensive muscular contractions, leads to alterations in SR Ca 2ϩ cycling, both lower Ca 2ϩ release and Ca 2ϩ uptake, and lower force (i.e., muscle fatigue) (2) . Curiously, intrinsic reductions in Ca 2ϩ uptake and Ca 2ϩ release, after various fatigue protocols, appear to be qualitatively and quantitatively similar (20, 42) . After eccentric exercise (20) , the time course (in days) for both the reduction and recovery in SR Ca 2ϩ uptake and Ca 2ϩ release is also closely associated. Moreover, in other models of muscular stress, such as ischemiareperfusion injury (28, 37) , a similar trend is observed, namely an apparent coupling between the reductions in both SR Ca 2ϩ uptake and Ca 2ϩ release. Conceivably, the apparent coupling could be explained by a common mechanism involving specific sites on the Ca 2ϩ -ATPase and the CRC and causing structural modifications to these proteins. Alternately, the possibility exists that the coupling is artifact, because of limitations in the measurement assays. In general, Ca 2ϩ release is measured after Ca 2ϩ uptake and SR Ca 2ϩ loading as part of the same assay.
Recently, we have also shown that 4 h of ischemia leads to a reduction in both SR Ca 2ϩ uptake and Ca 2ϩ release in both homogenates and isolated SR vesicles prepared from rat skeletal muscle (40) . In the ischemic study, we measured Ca 2ϩ release in vitro using silver nitrate (AgNO 3 ), which produced a biphasic Ca 2ϩ release response. There was an initial, rapid rate of release, which we called phase 1, followed by a more prolonged and slower rate of release, which we called phase 2. (14, 36) . If this is the case, inhibition of the Ca 2ϩ -ATPase by CPA could be responsible for the reduction in Ca 2ϩ release observed in phase 2. It is noteworthy that, in several previous reports utilizing AgNO 3 as the Ca 2ϩ -releasing agent, a two-phase response is clearly indicated but not used in the analyses (27, 29, 41) .
Understanding the specific effects of AgNO 3 on SR Ca 2 release and Ca 2ϩ -ATPase has important implications. On the one hand, if AgNO 3 has effects on both Ca 2ϩ cycling processes, the interpretation of the effects of perturbations such as exercise or ischemia would be biased. On the other had, if an intrinsic coupling does exist, this would represent an important advance in understanding the role of the SR in Ca 2ϩ regulation. In the present study, our objective was to examine the specific effects of AgNO 3 on the CRC and the Ca 2ϩ -ATPase to determine whether an intrinsic coupling does, in fact, exist between SR Ca 2ϩ uptake and Ca 2ϩ release or whether the effects that we have observed are specific only for AgNO 3 . To examine this issue, we used CPA, a specific inhibitor of the SR Ca 2ϩ -ATPase and Ca 2ϩ uptake (13, 33) , to inhibit SR Ca 2ϩ uptake during net Ca 2ϩ release, induced by either AgNO 3 or 4-chloro-m-cresol (4-CMC), which is known to directly activate the CRC (17) . Our findings indicate that AgNO 3 , but not 4-CMC, induces Ca 2ϩ release by acting on both the CRC and the Ca 2ϩ -ATPase.
METHODS
Animal description and care. Adult female Sprague-Dawley rats weighing between 225 and 275 g were housed in an environmentally controlled room (temperature 22-24°C, 40-60% relative humidity) with reversed light-dark cycles. Animals were fed ad libitum on laboratory chow and water until the time of the experiment. All experiments (muscle sampling) were initiated at approximately the same time each day to avoid large diurnal variations in muscle glycogen (6) . Experimental protocols were approved by the Animal Care Committee of the University of Waterloo.
Sample preparation for SR assessment in vitro. SpragueDawley rats (n ϭ 9) were weighed and anesthetized using an intraperitoneal injection of pentobarbital sodium (6 mg/100 g body wt). After anesthetization, the gastrocnemius muscle (both red and white portions), along with the entire tibialis anterior muscle, was excised from each limb and placed in ice-cold buffer to be used for preparation of muscle homogenates according to Heilmann et al. (16) . Mixed gastrocnemius and tibialis anterior muscles were diluted ϳ1:5 (wt/vol) in buffer containing (in mM) 5 HEPES (pH 7.5), 250 sucrose, 0.2% sodium azide, and 0.2 phenylmethylsulfonyl fluoride [no dithiothreitol (DTT)] and mechanically homogenized with a polytron homogenizer (PT 3100) at 16,500 rpm, for 2 ϫ 30-s bursts. Aliquots of muscle homogenate were then rapidly frozen in liquid nitrogen and stored at Ϫ70°C for later analysis of SR function.
SR Ca
2ϩ release measurements. AgNO3-induced Ca 2ϩ release was measured in muscle homogenates according to the methods of Ruell et al. (29) , using the Ca 2ϩ fluorescent dye indo 1, with minor modifications as previously described (40) . Fluorescence measurements were made on a spectrofluorometer (RatioMaster system, Photon Technology International) equipped with dual-emission monochromators. The measurement of cytoplasmic (buffer) free Ca 2ϩ ([Ca 2ϩ ]f) using the indo 1 procedure is based on the difference in the maximal emission wavelengths between the Ca 2ϩ -bound form of indo 1 and the Ca 2ϩ -free form. The excitation wavelength was 355 nm, and the emission maxima were 485 and 405 nm for Ca 2ϩ -free (G) and Ca 2ϩ -bound (F) indo 1, respectively. The ratio (R) of F to G is used to calculate [Ca 2ϩ ]f. With the use of Felix software (Photon Technology International), the ionized Ca 2ϩ concentration was calculated by the following equation (15) 
where Kd is the equilibrium constant for the interaction between Ca 2ϩ and indo 1, Rmin is the minimum value of R at the addition of 250 M EGTA, Gmax is the maximum value of G at the addition of 250 M EGTA, Gmin is the minimum value of G at the addition of 1 mM CaCl2, and Rmax is the maximum value of R at the addition of 1 mM CaCl2. The Kd value for the Ca 2ϩ -dye complex is 250 nM for muscle homogenates (15) .
Photon counts per second were recorded simultaneously for both emission wavelengths. The Ca 2ϩ -independent (background) fluorescence was measured in the reaction medium (without indo 1) at each emission wavelength before the experiment was started. Background fluorescence was automatically corrected before each assay was started using the Felix software.
The reaction buffer contained 200 mM KCl, 20 mM HEPES, 10 mM NaN 3, 5 M N,N,NЈ,NЈ-tetrakis(2-pyridylmethyl)ethylenediamine, 5 mM oxalate, and 15 mM MgCl2, pH 7.0. Before emission spectra were collected, 1.5 M indo 1 were added to a cuvette containing 2 ml of reaction buffer. In all trials, 2.5 l CaCl 2 (10 mM) were also added to the cuvette, which gave a consistent starting [Ca 2ϩ ]f of ϳ3.2 M. Immediately after data collection was initiated, 40 l of homogenate were added to the cuvette. Shortly after the addition of homogenate, 40 l of ATP were added, to give a final concentration of 5 mM and to initiate active Ca 2ϩ uptake and SR loading. Once the SR was loaded with Ca 2ϩ and a steady-state [Ca 2ϩ ]f Ͻ100 nM was achieved, 3 l of AgNO3 were added to give a final concentration of 141 M. The Ca 2ϩ release reaction was then allowed to proceed for ϳ3 min. Ca 2ϩ release was also induced by adding 10 l 4-CMC (final concentration ϭ 5 mM dissolved in dimethyl sulfoxide) in a subset of muscle homogenate samples (n ϭ 7). Dimethyl sulfoxide had no effect on Ca 2ϩ release. In some trials (n ϭ 5), 100 M of ruthenium red (RR) were added to the buffer at the start of the assay to check the specificity of both AgNO 3 and 4-CMC for the CRC.
Because it was important to determine whether Ca 2ϩ -ATPase inhibition causes a reduction in Ca 2ϩ release, which may be specific to the releasing agent, we used CPA to inhibit SR Ca 2ϩ -ATPase activity and Ca 2ϩ uptake. A 40 mM stock solution was prepared by dissolving CPA in chloroform. Chloroform alone had no effect on either Ca 2ϩ uptake or Ca 2ϩ release under these assay conditions. In the trials with CPA, 2 l of CPA (final concentration ϭ 40 M) were added after active loading of the SR with Ca 2ϩ and just before the addition of either AgNO3 or 4-CMC. To assess the specific impact of varying degrees of SR Ca 2ϩ -ATPase inhibition on SR Ca 2ϩ release with AgNO3, we also used concentrations of 2, 5, and 40 M CPA. Submaximal Ca 2ϩ uptake was inhibited by 51, 92, and 98% with 2, 5, and 40 M CPA, respectively (pilot data). CPA and the releasing agent (AgNO 3 or 4-CMC) were added in rapid succession to prevent CPAinduced SR Ca 2ϩ leakage before Ca 2ϩ release was initiated. We assessed the extent of Ca 2ϩ leakage induced by CPA alone, which averaged 26.8 Ϯ 0.5 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 . On addition of both AgNO3 and 4-CMC, Ca 2ϩ release consistently proceeded in two distinct phases. There was an initial, rapid rate of release (phase 1) followed by a slower, more prolonged rate of release (phase 2) (see Fig. 1 ). The generated curve from Eq. 1 was smoothed over 21 points and differentiated. The maximal rate of Ca 2ϩ release for each phase was calculated by taking the maximum positive derivative of each phase expressed in moles per gram protein per minute. In general, phase 1, which began with the initial increase in [Ca 2ϩ ]f, was complete in the first few seconds. In contrast, phase 2 extended for 2-3 min. Protein was determined by the method of Lowry, as modified by Schacterle and Pollock (32) . On a given day, all samples for a given variable were analyzed in duplicate.
SR Ca 2ϩ -ATPase activity measurements. Spectrophotometric (Schimadzu UV 160U) measurement of SR Ca 2ϩ -
ATPase activity was performed on homogenates using procedures developed by Simonides and van Hardeveld (35) , with minor modifications as previously described (38) . Total (Mg 2ϩ -activated)-ATPase activity was measured in the presence of ϳ6-10 M [Ca 2ϩ ]f to obtain maximal ATPase activity and in the presence of the Ca 2ϩ ionophore A-23187. Basal activity was measured in the presence of 40 M CPA, which completely inhibits SR Ca 2ϩ -ATPase activity (33) . The difference between total and basal activities represents the Ca 2ϩ -activated ATPase activity. To assess the effect of both AgNO 3 and 4-CMC on SR Ca 2ϩ -ATPase activity, in 50% of the trials either 141 M AgNO 3 or 5 M 4-CMC were added to the cuvette after maximal Ca 2ϩ -ATPase activity was obtained and before basal activity was obtained. Both Ca 2ϩ -ATPase activity and basal activity were expressed in micromoles per gram protein per minute. On a given analytic day, samples from all conditions were analyzed in duplicate.
Data analysis. For Ca 2ϩ release measurements with and without 40 M CPA and 100 M RR, a two-way ANOVA was used to discriminate between differences due to CPA or RR (with vs. without) and releasing agent (AgNO 3 vs. 4-CMC).
Where an overall interaction between assay and group was found, post hoc analyses (Tukey's) were performed to determine specific assay and group effects. For AgNO 3-induced Ca 2ϩ release measurements made in the presence of varying CPA concentrations, a one-way ANOVA was used to test for differences between means. Where significant differences were found, Tukey's post hoc tests were used to compare specific means. For all other measurements, two-tailed paired t-tests were used to test for differences between means. For all comparisons, statistical significance was accepted at P Ͻ 0.05. All data are expressed as means Ϯ SE.
RESULTS

Ca
2ϩ release with AgNO 3 . With the addition of AgNO 3 , Ca 2ϩ release proceeded in two distinct phases: an initial, rapid rate of release that was complete within seconds (phase 1), followed by a slower, more prolonged rate of release (phase 2) (Fig. 1A) , which lasted 2-3 min until Ca 2ϩ release stopped and the buffer [Ca 2ϩ ] f plateaued at some level (data not shown). The effects of CPA were opposite on these two phases of Ca 2ϩ release. In all conditions, inhibition of Ca 2ϩ -ATPase activity with CPA after loading of SR with Ca 2ϩ increased (P Ͻ 0.05) the early, rapid rate of release and decreased (P Ͻ 0.05) the slower, more prolonged rate of release. The same results are obtained with isolated SR vesicles (data not shown). The percent change in Ca 2ϩ release rate was altered with varying concentrations of CPA, and, therefore, the extent of SR Ca 2ϩ -ATPase inhibition, for phase 2 but not for phase 1. A typical response for one animal showing the effects of different CPA concentrations on Ca 2ϩ release is shown in Fig. 2 . On average, phase 2 Ca 2ϩ release rate was reduced (P Ͻ 0.05) by 44, 57, and 72% with 2, 5, and 40 M CPA, respectively, compared with no CPA (Fig. 3) . However, the average increase in phase 1 Ca 2ϩ release rate with CPA was similar across all CPA concentrations used.
Ca 2ϩ release with 4-CMC. The biphasic Ca 2ϩ release rate response induced by 4-CMC was similar to the AgNO 3 -induced Ca 2ϩ release rate response (Fig. 1B) . However, the absolute release rate for phase 1 was approximately sixfold higher (P Ͻ 0.05) with 4-CMC compared with AgNO 3 (1,961 Ϯ 112 vs. 314 Ϯ 51 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 ). There were no differences (P Ͼ 0.05) in the absolute rate of release for phase 2 between 4-CMC and AgNO 3 (281 Ϯ 17.1 vs. 267 Ϯ 39 mol ⅐ g protein Ϫ1 ⅐ min Ϫ1 , respectively). Unlike AgNO 3 , 40 M CPA after Ca 2ϩ loading of the SR had no effect on the 4-CMC-induced rate of release corresponding with both phase 1 and phase 2 (Fig. 4) . (Fig. 6) . Ca 2ϩ -ATPase activity in the presence of AgNO 3 was not different (P Ͼ 0.05) from basal activity. Even concentrations as low as 5 M AgNO 3 appeared to partially inhibit Ca 2ϩ -ATPase activity (data not shown). Surprisingly, we also found that 4-CMC inhibited Ca 2ϩ -ATPase activity by 97 Ϯ 1.4%.
DISCUSSION
The purpose of this study was to determine whether SR Ca 2ϩ uptake and Ca 2ϩ release are intrinsically coupled or whether the apparent coupling that has been observed is specific to the Ca 2ϩ -releasing agent employed. We have demonstrated that AgNO 3 induces a biphasic Ca 2ϩ release rate response measured in homogenates in vitro, as we have shown previously (40) . We also confirmed our earlier finding, namely that Ca 2ϩ -ATPase inhibition with CPA administered after SR Ca 2ϩ loading and before inducing Ca 2ϩ release causes a reduction in Ca 2ϩ release rate (phase 2). However, this effect is only specific for AgNO 3 . If Ca 2ϩ release is induced with 4-CMC, inhibition of the Ca 2ϩ -ATPase with CPA after Ca 2ϩ loading has no effect on either phase of Ca 2ϩ release. Moreover, blocking the CRC with RR had no effect on phase 1 and inhibited phase 2 by 65% when AgNO 3 was used. When 4-CMC was employed as the releasing agent in conjunction with RR, phase 1 was reduced by 59%, and phase 2 was completely blocked. These results suggest that AgNO 3 , in contrast to 4-CMC, has a unique effect on Ca 2ϩ - Fig. 2 . Concentration-dependent effects of cyclopiazonic acid (CPA) in muscle homogenates on Ca 2ϩ release kinetics during a typical assay in phase 1 and phase 2. ATPase activity, resulting in reversal of the pump and extrusion of Ca 2ϩ into the cytosol. Recently, Ikemoto and colleagues (18, 30) release that we observed previously (38) and the observation from the literature that reductions in Ca 2ϩ uptake and Ca 2ϩ release after exercise (20, 42) and ischemia-reperfusion are closely matched (28, 37) . However, in this experiment, we wanted to examine whether such a relationship exists intrinsically after the SR was loaded with Ca 2ϩ or whether the relationship is specific to AgNO 3 .
To investigate this problem, it was first necessary to demonstrate that the reduction in AgNO 3 -induced Ca 2ϩ release (phase 2) due to inhibition of the Ca 2ϩ -ATPase with CPA is a general phenomenon and is not just specific for AgNO 3 . In fact, we found that CPA had no effect on the rate of Ca 2ϩ release for either phase when 4-CMC was employed as the Ca 2ϩ releasing agent. Although this does not contradict the findings by Ikemoto and Yamamoto (18) release from Ca 2ϩ -loaded SR vesicles, which is related to their binding affinity for sulfhydryl groups (1). In the case of Ag ϩ , it has been reported that the rate of Ca 2ϩ release is five to six times higher in heavy SR vesicles compared with light SR vesicles and that Ca 2ϩ release could be blocked by procaine, tetracaine, and RR, now well-known inhibitors of the CRC (31) . Based on these results, it was argued that heavy metals and specifically Ag ϩ (AgNO 3 ) induce Ca 2ϩ release from SR vesicles by interacting with the CRC and not the Ca 2ϩ -ATPase (31) . In addition, single-channel activity measurements demonstrated the ability of Ag ϩ to directly activate the CRC (25) .
However, in the study by Salama and Abramson (31), the light SR vesicles, in which the Ca 2ϩ -ATPase comprises 90% of the total protein (19) , released 90-100% of the accumulated Ca 2ϩ in the presence of AgNO 3 . Moreover, the Ca 2ϩ -ATPase comprises 55-65% of total heavy SR vesicle protein (19) . It is also well known that the SR Ca 2ϩ -ATPase contains 24 cysteine residues (3) and is highly susceptible to sulf- hydryl oxidation (34, 43) . Given these considerations, it is difficult to rule out the involvement of the Ca 2ϩ -ATPase in the AgNO 3 -induced Ca 2ϩ release response in SR vesicles.
The most compelling evidence to date that Ag ϩ can induce Ca 2ϩ release by interaction with the Ca 2ϩ -ATPase comes from a study by Gould et al. (14) in which they showed a rapid Ca 2ϩ efflux induced by Ag ϩ from reconstituted vesicles that contained the purified Ca 2ϩ -ATPase as the only protein.
As we have shown for homogenates in the present study, they also showed that Ag ϩ greatly inhibited Ca 2ϩ -ATPase activity in both reconstituted vesicles and SR vesicles. Evidence from other cell types, such as liver (44) and HL-60 (36), suggests that heavy metals (including Ag ϩ ) induce Ca 2ϩ release from intracellular stores mainly due to inhibition of the Ca 2ϩ -ATPase in conjunction with a direct effect on the CRC. In liver cells, both RR and tetracaine have no effect on Ca 2ϩ efflux induced by heavy metals (44) .
Our results strongly support a dual action of AgNO 3 for inducing Ca 2ϩ release, at least from muscle homogenates prepared from rat skeletal muscle. Similar to HL-60 cells, it appears that AgNO 3 induces a rapid Ca 2ϩ efflux from muscle homogenates by simultaneously interacting with both the CRC and the Ca 2ϩ -ATPase of the SR. The effects of RR on the AgNO 3 -induced Ca 2ϩ release response provides evidence that AgNO 3 directly activates the CRC. However, only phase 2 was inhibited with RR, and the extent of inhibition was only 65% compared with 100% for 4-CMC-induced Ca 2ϩ release. This suggests that only part of the AgNO 3 -induced Ca 2ϩ release response can be explained by activation of the CRC. Nonetheless, the CRC does contribute to AgNO 3 -induced Ca 2ϩ release as expected, and recent work using single-channel analysis confirms that AgNO 3 directly activates both the skeletal muscle CRC isoform (ryanodine receptor 1) and the cardiac isoform (ryanodine receptor 2) (G. G. Du, personal communication) .
In previous studies, it was shown that 4 mM DTT completely blocked AgNO 3 -induced Ca 2ϩ release from skeletal muscle samples (29, 41) . In these studies, DTT, as opposed to RR, was used to validate the Ca 2ϩ release assay using AgNO 3 and to demonstrate the specificity of AgNO 3 for the CRC. However, DTT is a sulfhydryl-reducing agent that is not specific for any particular protein (5), and we have shown that DTT can alter the effects of skeletal muscle ischemia on measurements of SR Ca 2ϩ -ATPase activity (39) . In HL-60 cells, it was concluded that the apparent Ca 2ϩ release induced by AgNO 3 was mainly due to inhibition of the Ca 2ϩ pump with increased permeability for Ca 2ϩ (10) . This mechanism cannot explain the rapid AgNO 3 -induced Ca 2ϩ release response observed in the present study. Even though AgNO 3 completely inhibited Ca 2ϩ -ATPase activity, the rate of Ca 2ϩ leak due to Ca 2ϩ -ATPase inhibition alone that we observed only represented ϳ12% of the AgNO 3 -induced rate of release in phase 2. Moreover, CPA reduced the AgNO 3 -induced rate of release corresponding to phase 2 by 72% and, importantly, had no effect on 4-CMC-induced Ca 2ϩ release. In the presence of lower CPA concentrations, the extent of inhibition of Ca 2ϩ release for phase 2 was also lower. Because CPA can inhibit the Ca 2ϩ -ATPase in both directions (forward and reverse) (10, 11) but cannot reduce the leak of calcium ions through the Ca 2ϩ -ATPase passive channel (10) , it would appear that AgNO 3 triggers the reversal of the Ca 2ϩ -ATPase and thus Ca 2ϩ release through this pathway. Interestingly, 4-CMC also inhibited Ca 2ϩ -ATPase activity. However, because Ca 2ϩ release (phase 2) was completely blocked when 4-CMC was combined with RR, inhibition of Ca 2ϩ -ATPase would appear to be specific for the forward direction only.
Gould et al. (14) proposed a similar mechanism in reconstituted vesicles, suggesting that the Ca 2ϩ binding sites on the Ca 2ϩ -ATPase could remain in a lowaffinity state and cycle between the luminal and cytoplasmic side of the SR membrane, thus releasing Ca 2ϩ into the cytoplasm (14) . Other studies have also shown that the Ca 2ϩ -ATPase can be reversed under various conditions and can synthesize ATP from ADP and P i (7) (8) (9) .
The nature of the Ca 2ϩ release response for phase 1 induced by AgNO 3 is unclear from our data. We have found that various concentrations of CPA increased the rate of release by a similar extent. If phase 1 reflects Ca 2ϩ release solely from the CRC, this finding would be expected, providing the rate of Ca 2ϩ release simply reflects a balance between the rate of release and reuptake of Ca 2ϩ during release. On the other hand, because AgNO 3 completely inhibits Ca 2ϩ -ATPase activity, the increase in phase 1 Ca 2ϩ release in the presence of CPA is not due to reduced Ca 2ϩ uptake during release. Moreover, RR had no effect on phase 1 Ca 2ϩ release induced by AgNO 3 , whereas phase 1 Ca 2ϩ release induced by 4-CMC was inhibited by 59% with RR. Thus the CPA and RR results do not support a role for either the Ca 2ϩ -ATPase or the CRC for the early, rapid rate of Ca 2ϩ release induced by AgNO 3 . The fact that 4-CMC-induced release corresponding to phase 1 was not completely blocked by RR is consistent with the known mechanism for RR blockade of the CRC. RR blocks the channel conduction pore of an open CRC but does not inactivate the CRC or prevent the CRC from opening (4, 22) . Therefore, despite RR being present at the start of each assay, addition of 4-CMC would activate the channel and induce Ca 2ϩ release until RR moved into the channel conduction pore to block further release of Ca 2ϩ . The question might be asked as to whether the effects of AgNO 3 might be different with whole muscle homogenates as used in this experiment and enriched SR fractions that contain primarily only the Ca 2ϩ -ATPase. Measurement of the Ca 2ϩ -ATPase in whole homogenates is highly specific as a result of the selective inhibition of other cellular ATPases (29, 35) . Moreover, we have shown that Ca 2ϩ release induced from enriched SR preparations demonstrates a similar biphasic release as whole homogenates and is affected by CPA in a similar manner (unpublished observations). These observations would suggest that the effects of AgNO 3 do not depend on the type of preparation.
The results from the present study suggest that 4-CMC is a much better agent to assess CRC function in vitro compared with AgNO 3 . First, 4-CMC is a much more potent activator of the CRC than AgNO 3 , as reflected by the different rates of release corresponding to phase 1 for the two chemicals. A similar result was reported previously (27) . As well, 4-CMC has a higher affinity for the CRC than caffeine (17) . Second, and most importantly, 4-CMC is specific for the CRC, as shown previously (17) , whereas AgNO 3 affects both the Ca 2ϩ -ATPase and the CRC. There is also evidence that Ag ϩ binds to sulfhydryl groups of the dihydropyridine receptor (26) and enhances ryanodine contracture of the mouse diaphragm (21) . Thus interpretation of data is complicated at best when AgNO 3 is used to assess Ca 2ϩ release function.
Perspectives. There are several implications that can be drawn from the results of these experiments. One obvious implication is the selection of the releasing agent. For most experiments, a releasing agent that is highly sensitive and specific for the CRC is desirable. It would appear the 4-CMC meets these criteria. Moreover, experiments with CPA clearly indicate that neither phase of Ca 2ϩ release rate is affected by inhibition of Ca 2ϩ -ATPase activity when the SR vesicles are loaded with Ca 2ϩ . Our results also suggest that both phase 1 and phase 2 are distinct entities and should be assessed routinely. Finally, our findings would appear to have important implications to the interpretations of acute exercise experiments when AgNO 3 is used as the CRC releasing agent. Exercise-induced inhibition of Ca 2ϩ -ATPase activity could effectively result in alterations of Ca 2ϩ release (increase in phase 1 and decrease in phase 2), not only because of the inhibition of the pump per se, which would affect Ca 2ϩ loading into SR, but because of the reversal of pump function caused by AgNO 3 . In this regard, the effect would be similar to that observed when CPA is used in conjunction with AgNO 3 . As with any in vitro preparation, the issue of physiological relevance is important. Our experiments were performed on homogenates and in highly contrived environments. Under these conditions, Ca 2ϩ uptake and Ca 2ϩ release rates occur over a much longer time frame than that observed in vivo. However, the value of in vitro models is that specific factors can be studied in isolation and the underlying mechanisms for any observed effects can be examined.
